## **Armand Keating**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6069256/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mesenchymal Stromal Cells: New Directions. Cell Stem Cell, 2012, 10, 709-716.	5.2	679
2	Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. Journal of Clinical Investigation, 2006, 116, 1865-1877.	3.9	468
3	Mesenchymal stromal cells. Current Opinion in Hematology, 2006, 13, 419-425.	1.2	315
4	Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Research in Cardiology, 2011, 106, 1299-1310.	2.5	221
5	Bone Marrow-Derived Mesenchymal Stromal Cells Express Cardiac-Specific Markers, Retain the Stromal Phenotype, and Do Not Become Functional Cardiomyocytes In Vitro. Stem Cells, 2008, 26, 2884-2892.	1.4	202
6	Biology of Bone Marrow Stroma. Annals of the New York Academy of Sciences, 1995, 770, 70-78.	1.8	180
7	Doxorubicin onjugated Immunoâ€Nanoparticles for Intracellular Anticancer Drug Delivery. Advanced Functional Materials, 2009, 19, 1689-1696.	7.8	171
8	A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget, 2017, 8, 89256-89268.	0.8	127
9	Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties. Journal of Hematology and Oncology, 2018, 11, 82.	6.9	114
10	TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling. Stem Cells, 2017, 35, 265-275.	1.4	106
11	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2018, 5, e563-e598.	2.2	97
12	Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Research and Therapy, 2019, 10, 117.	2.4	97
13	Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. Journal of Clinical Oncology, 2000, 18, 3690-3698.	0.8	91
14	Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. British Journal of Haematology, 2001, 113, 202-208.	1.2	79
15	The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‣ensitive Relapsed and Primary Refractory Nonâ€Hodgkinâ∈™s Lymphoma: Identification of Major Prognostic Groups. British Journal of Haematology, 1996, 92, 880-889.	1.2	73
16	CD34 antigen: Molecular features and potential clinical applications. Stem Cells, 1993, 11, 50-57.	1.4	67
17	Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nature Biotechnology, 2014, 32, 724-726.	9.4	62
18	Immunomodulatory Properties of Coriolus versicolor: The Role of Polysaccharopeptide. Frontiers in Immunology, 2017, 8, 1087.	2.2	62

#	Article	IF	CITATIONS
19	Collagen scaffold enhances the regenerative properties of mesenchymal stromal cells. PLoS ONE, 2017, 12, e0187348.	1.1	60
20	Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Frontiers in Immunology, 2018, 9, 267.	2.2	57
21	Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. British Journal of Haematology, 1998, 103, 711-715.	1.2	53
22	Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica, 2012, 97, 1020-1028.	1.7	53
23	Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica, 2013, 98, 185-192.	1.7	50
24	Human Umbilical Cord Perivascular Cells Exhibit Enhanced Cardiomyocyte Reprogramming and Cardiac Function after Experimental Acute Myocardial Infarction. Cell Transplantation, 2013, 22, 1651-1666.	1.2	45
25	Effect of radiation and cell implantation on wound healing in a rat model. Journal of Surgical Oncology, 2003, 83, 185-190.	0.8	40
26	Differential Immunomodulatory Effects of Human Bone Marrow-Derived Mesenchymal Stromal Cells on Natural Killer Cells. Stem Cells and Development, 2019, 28, 933-943.	1.1	37
27	Illness intrusiveness among survivors of autologous blood and marrow transplantation. Cancer, 2001, 92, 3147-3154.	2.0	36
28	Concise Review: TLR Pathway-miRNA Interplay in Mesenchymal Stromal Cells: Regulatory Roles and Therapeutic Directions. Stem Cells, 2018, 36, 1655-1662.	1.4	36
29	Successful pregnancy and delivery during α-interferon therapy for chronic myeloid leukemia. American Journal of Hematology, 1992, 40, 238-239.	2.0	35
30	A Phase I Study of the Transplantation of Genetically Marked Autologous Bone Marrow Stromal Cells. University of Toronto, Ontario, Canada. Human Gene Therapy, 1998, 9, 591-600.	1.4	32
31	Cell-Based Therapies for Osteonecrosis of the Femoral Head. Biology of Blood and Marrow Transplantation, 2008, 14, 1081-1087.	2.0	30
32	Prodrugs and prodrug-activated systems in gene therapy. Molecular Therapy, 2021, 29, 1716-1728.	3.7	26
33	Mini-beam as Salvage Chemotherapy for Refractory Hodgkin's Disease and Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1991, 5, 111-115.	0.6	24
34	Group V Phospholipase A2 in Bone Marrow-derived Myeloid Cells and Bronchial Epithelial Cells Promotes Bacterial Clearance after Escherichia coli Pneumonia. Journal of Biological Chemistry, 2011, 286, 35650-35662.	1.6	22
35	Sca-1+Linâ~'CD117â~' Mesenchymal Stem/Stromal Cells Induce the Generation of Novel IRF8-Controlled Regulatory Dendritic Cells through Notch–RBP-J Signaling. Journal of Immunology, 2015, 194, 4298-4308.	0.4	22
36	Cell Therapy for Knee Osteoarthritis: Mesenchymal Stromal Cells. Gerontology, 2019, 65, 294-298.	1.4	20

#	Article	IF	CITATIONS
37	Results of Therapy for Acute Myeloid Leukemia in First Relapse. Leukemia and Lymphoma, 1991, 6, 15-24.	0.6	19
38	Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model. Journal of Heart and Lung Transplantation, 2015, 34, 1481-1488.	0.3	19
39	Bone Marrow Therapies for Chronic Heart Disease. Stem Cells, 2015, 33, 3212-3227.	1.4	18
40	CD16 <sup>+</sup> NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica, 2018, 103, 1720-1729.	1.7	18
41	MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131â^' epitope expressed by leukemia stem cells. Leukemia Research, 2014, 38, 1367-1373.	0.4	16
42	Banking Mesenchymal Stromal Cells from Umbilical Cord Tissue: Large Sample Size Analysis Reveals Consistency Between Donors. Stem Cells Translational Medicine, 2019, 8, 1041-1054.	1.6	16
43	OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells. PLoS ONE, 2017, 12, e0189131.	1.1	16
44	Donor Mesenchymal Stromal Cells (MSCs) Undergo Variable Cardiac Reprogramming in Vivo and Predominantly Co-Express Cardiac and Stromal Determinants after Experimental Acute Myocardial Infarction. Stem Cell Reviews and Reports, 2014, 10, 304-315.	5.6	15
45	A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Research Reports, 2015, 4, 55-59.	0.2	15
46	Rapid isolation of bone marrow mesenchymal stromal cells using integrated centrifuge-based technology. Cytotherapy, 2016, 18, 729-739.	0.3	15
47	Mesenchymal stromal cell therapy to promote cardiac tissue regeneration and repair. Current Opinion in Organ Transplantation, 2017, 22, 86-96.	0.8	14
48	Investigation ofbcr‐abltranscription by ph‐positive chronic myeloid leukemia progenitors. Stem Cells, 1993, 11, 31-33.	1.4	13
49	Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy, 2010, 12, 951-960.	0.3	13
50	Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1. Blood Cancer Journal, 2019, 9, 6.	2.8	13
51	Generation of Functional Hepatocytes from Human Adipose-Derived MYC+ KLF4+ GMNN+ Stem Cells Analyzed by Single-Cell RNA-Seq Profiling. Stem Cells Translational Medicine, 2018, 7, 792-805.	1.6	12
52	Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Medical Hypotheses, 2015, 84, 169-177.	0.8	11
53	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 405-411.	2.0	11
54	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematology,the, 2022, 9, e374-e384.	2.2	11

#	Article	IF	CITATIONS
55	Ciprofloxacin-induced neutropenia and erythema multiforme. American Journal of Hematology, 1993, 43, 159-160.	2.0	10
56	Human Mesenchymal Stromal Cells Improve Cardiac Perfusion in an Ovine Immunocompetent Animal Model. Journal of Investigative Surgery, 2016, 29, 218-225.	0.6	8
57	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis Blood, 2006, 108, 2007-2007.	0.6	7
58	Photodynamic Elimination of Clonogenic PH+ Chronic Myeloid Leukemia Cells. Leukemia and Lymphoma, 1993, 11, 265-269.	0.6	6
59	Topical Application of Culture-Expanded CD34+ Umbilical Cord Blood Cells from Frozen Units Accelerates Healing of Diabetic Skin Wounds in Mice. Stem Cells Translational Medicine, 2018, 7, 591-601.	1.6	6
60	Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation. Leukemia and Lymphoma, 1991, 4, 231-238.	0.6	5
61	Bone marrow cells for cardiac repair. Biology of Blood and Marrow Transplantation, 2005, 11, 2-6.	2.0	5
62	Addition of Rituximab to CHOP Is an Attractive Strategy as Primary Therapy for Diffuse Large B Cell Lymphoma (DLBCL) in Patients Age <60 Years: An Economic Analysis Blood, 2004, 104, 3126-3126.	0.6	5
63	Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell–derived IL-6 is reversed predominantly by IL-6 blockade. Cytotherapy, 2022, 24, 699-710.	0.3	5
64	T-Cell Blast Crisis in Chronic Myeloid Leukemia. Leukemia and Lymphoma, 1991, 3, 319-324.	0.6	2
65	Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral. Blood, 2019, 134, 768-768.	0.6	2
66	Expression of Factor IX cDNA Introduced into Human Marrow Stromal Cells by Electroporation. Hematology, 1998, 3, 347-354.	0.7	1
67	Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma. Bone Marrow Transplantation, 2018, 53, 347-351.	1.3	1
68	Human mesenchymal stromal cells do not promote recurrence of soft tissue sarcomas in mouse xenografts after radiation and surgery. Cytotherapy, 2018, 20, 1001-1012.	0.3	1
69	Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. Leukemia and Lymphoma, 2020, 61, 2153-2160.	0.6	1
70	Outcomes of Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B Cell Lymphoma (PMLCL) Are Inferior to Diffuse Large B Cell Lymphoma (DLBCL) Blood, 2005, 106, 2085-2085.	0.6	1
71	Highlights of the 19th Annual Meeting of the International Society for Experimental Hematology (ISEH) Held in Seattle, Washington, USA, August 26–30, 1990. Leukemia and Lymphoma, 1991, 4, 425-428.	0.6	0
72	Current Treatment of Chronic Myeloid Leukemia. Hematology, 2001, 6, 1-17.	0.7	0

5

#	Article	IF	CITATIONS
73	Anticancer Drug Delivery: Doxorubicin-Conjugated Immuno-Nanoparticles for Intracellular Anticancer Drug Delivery (Adv. Funct. Mater. 11/2009). Advanced Functional Materials, 2009, 19, NA-NA.	7.8	0
74	Autologous Gamma-Delta T (GD-T) Cells in Acute Myeloid Leukemia (AML): Potential Immune Effector Cells for Minimal Disease? Blood, 2004, 104, 2538-2538.	0.6	0
75	Superior Cytotoxicity of Clonal Versus Polyclonal Gamma Delta T Cells against Philadelphia Chromosome Positive and B-CLL Derived Leukemic Cells Blood, 2009, 114, 3032-3032.	0.6	0
76	Preliminary Results of FDG-PET Scanning after GDP Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Relapsed/Refractory (RR) Lymphoma. Blood, 2016, 128, 4645-4645.	0.6	0
77	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
78	Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression. Blood, 2018, 132, 1532-1532.	0.6	0
79	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 2719-2719.	0.6	0
80	Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival. Blood, 2019, 134, 4616-4616.	0.6	0
81	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	0.6	0
82	Treatment of COVID-19 with MSCs: how does it work?. Science China Life Sciences, 2021, , 1.	2.3	0
83	Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma. Blood, 2021, 138, 655-655.	0.6	0